

Teh-Ia Huo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8235517/publications.pdf>

Version: 2024-02-01

288
papers

8,030
citations

50276

46
h-index

76900

74
g-index

289
all docs

289
docs citations

289
times ranked

8265
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Utility of Albumin Bilirubin Grade as a Prognostic Marker in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: a Systematic Review and Meta-analysis. <i>Journal of Gastrointestinal Cancer</i> , 2023, 54, 420-432.	1.3	8
2	Cryptogenic hepatocellular carcinoma: characteristics, outcome, and prognostic role of albumin-bilirubin (ALBI) grade vs easy ALBI grade. <i>Scandinavian Journal of Gastroenterology</i> , 2023, 58, 61-69.	1.5	4
3	Oncogenic circRNA C190 Promotes Non-Small Cell Lung Cancer via Modulation of the EGFR/ERK Pathway. <i>Cancer Research</i> , 2022, 82, 75-89.	0.9	48
4	A New Tumor Burden Score and Albumin-Bilirubin Grade-Based Prognostic Model for Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 649.	3.7	17
5	Improving the accuracy of outcome prediction for hepatocellular carcinoma: Asia strategies. <i>Liver International</i> , 2022, 42, 714-715.	3.9	0
6	Dual hepatitis B and C-associated hepatocellular carcinoma: clinical characteristics, outcome, and prognostic role of albumin-bilirubin grade. <i>International Journal of Clinical Oncology</i> , 2022, 27, 739-748.	2.2	5
7	Glutathione S-transferase in hepatocellular carcinoma: Is it an authentic clinical prognostic predictor?. <i>Liver International</i> , 2022, 42, 1475-1475.	3.9	1
8	Surgical resection could provide better outcomes for patients with hepatocellular carcinoma and tumor rupture. <i>Scientific Reports</i> , 2022, 12, 8343.	3.3	5
9	Albumin-Bilirubin (ALBI) Grade-Based Nomogram for Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. <i>Digestive Diseases and Sciences</i> , 2021, 66, 1730-1738.	2.3	10
10	Letter to the Editor: Using Circulating Biomarkers to Stage HCC: Pitfalls and Limitations. <i>Hepatology</i> , 2021, 73, 2611-2611.	7.3	0
11	Active Vitamin D Treatment Attenuated Bacterial Translocation via Improving Intestinal Barriers in Cirrhotic Rats. <i>Molecular Nutrition and Food Research</i> , 2021, 65, e2000937.	3.3	20
12	Changing faces of hepatocellular carcinoma: East vs West. <i>Liver International</i> , 2021, 41, 1430-1431.	3.9	3
13	Comparison of Seven Noninvasive Models for Predicting Decompensation and Hospitalization in Patients with Cirrhosis. <i>Digestive Diseases and Sciences</i> , 2021, 66, 4508-4517.	2.3	9
14	METTL3-dependent N ⁶ -methyladenosine RNA modification mediates the atherogenic inflammatory cascades in vascular endothelium. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	68
15	Changing patterns of etiology and management of hepatocellular carcinoma: need for global reappraisal. <i>Journal of Gastroenterology</i> , 2021, 56, 406-407.	5.1	1
16	Post hepatitis B-eliminated hepatocellular carcinoma: New challenges. <i>Liver International</i> , 2021, 41, 1173-1174.	3.9	0
17	Persistent liver inflammation in chronic hepatitis C patients with advanced fibrosis after direct-acting antivirals induced sustained virological response. <i>Journal of the Chinese Medical Association</i> , 2021, 84, 472-477.	1.4	2
18	ALBI grade in dialysis patients with hepatocellular carcinoma: prognostic impact and staging strategy. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 722-734.	1.4	1

#	ARTICLE	IF	CITATIONS
19	Eritoran Attenuates Hepatic Inflammation and Fibrosis in Mice with Chronic Liver Injury. <i>Cells</i> , 2021, 10, 1562.	4.1	12
20	Easy albuminâ€“bilirubin score as a new prognostic predictor in hepatocellular carcinoma. <i>Hepatology Research</i> , 2021, 51, 1129-1138.	3.4	17
21	Tumor burden score as a new prognostic marker for patients with hepatocellular carcinoma undergoing transarterial chemoembolization. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 3196-3203.	2.8	21
22	Early and late recurrence of surgically resected hepatitis B virus-related hepatocellular carcinoma on nucleos(t)ide analogues therapy. <i>Journal of the Formosan Medical Association</i> , 2021, 120, 1563-1571.	1.7	14
23	Dual DNA Transfection Using 1,6-Hexanedithiol-Conjugated Maleimide-Functionalized PU-PEI600 For Gene Correction in a Patient iPSC-Derived Fabry Cardiomyopathy Model. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 634190.	3.7	1
24	Selecting an optimal prognostic model for advanced hepatocellular carcinoma: Any new ideas?. <i>Digestive and Liver Disease</i> , 2021, 53, 1208-1209.	0.9	1
25	Nomogram for surgical hepatocellular carcinoma: What have we missed?. <i>Liver International</i> , 2021, 41, 3034-3035.	3.9	5
26	(Pro)renin Receptor Knockdown Attenuates Liver Fibrosis Through Inactivation of ERK/TGF-Î²1/SMAD3 Pathway. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021, 12, 813-838.	4.5	13
27	Predicting microvascular invasion in HCC with ctDNA: What are the pitfalls?. <i>Liver International</i> , 2021, 41, 1148-1149.	3.9	2
28	Improved patient survival in hepatitis C virusâ€“related hepatocellular carcinoma: Do directâ€“acting antivirals play a role?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, , .	2.8	0
29	Outstanding research paper awards of the Journal of the Chinese Medical Association in 2020. <i>Journal of the Chinese Medical Association</i> , 2021, Publish Ahead of Print, .	1.4	1
30	Comment on â€œEffect of Microvascular Invasion Risk on Early Recurrence of Hepatocellular Carcinoma After Surgery and Radiofrequency Ablationâ€“. <i>Annals of Surgery</i> , 2021, 274, e101-e102.	4.2	0
31	Nanodiamond-based microRNA delivery system promotes pluripotent stem cells toward myocardiogenic reprogramming. <i>Journal of the Chinese Medical Association</i> , 2021, 84, 177-182.	1.4	6
32	Predictors of long-term recurrence and survival after resection of HBV-related hepatocellular carcinoma: the role of HBsAg. <i>American Journal of Cancer Research</i> , 2021, 11, 3711-3725.	1.4	4
33	Prognostic prediction for patients with hepatocellular carcinoma receiving immunotherapy: Are we there yet?. <i>Journal of Hepatology</i> , 2021, , .	3.7	1
34	Comparable benefits of HCV eradication by direct acting antivirals and interferon-based therapy in patients with hepatocellular carcinoma undergoing surgical resection. <i>American Journal of Cancer Research</i> , 2021, 11, 5526-5542.	1.4	0
35	Look for a Physical Health Status Surrogate in Hepatocellular Carcinoma: Have we Found the Holy Grail?. <i>Clinical Gastroenterology and Hepatology</i> , 2021, , .	4.4	0
36	Aspirin is associated with low recurrent risk in hepatitis B virus-related hepatocellular carcinoma patients after curative resection. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 218-229.	1.7	19

#	ARTICLE	IF	CITATIONS
37	Association between esophagogastric varices in hepatocellular carcinoma and poor prognosis after transarterial chemoembolization: A propensity score matching analysis. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 610-620.	1.7	13
38	Evolution of hepatocellular carcinoma: non-B, non-C and beyond. <i>Journal of Gastroenterology</i> , 2020, 55, 123-124.	5.1	0
39	Albuminâ€bilirubin gradeâ€based nomogram of the BCLC system for personalized prognostic prediction in hepatocellular carcinoma. <i>Liver International</i> , 2020, 40, 205-214.	3.9	28
40	A New Prognostic Model Based on Albuminâ€Bilirubin Grade for Hepatocellular Carcinoma Beyond the Milan Criteria. <i>Digestive Diseases and Sciences</i> , 2020, 65, 658-667.	2.3	14
41	Too Many versus Too Few Platelets in Patients with Hepatocellular Carcinoma: Good or Bad?. <i>Liver Cancer</i> , 2020, 9, 108-109.	7.7	1
42	Low dose of propranolol treatment is associated with better survival in cirrhotic patients with hepatic encephalopathy. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 365-372.	1.6	2
43	Are inflammationâ€based models feasible tools in predicting the outcome of patients with hepatocellular carcinoma?. <i>Liver International</i> , 2020, 40, 1498-1498.	3.9	2
44	Stereotactic body radiation therapy vs. radiofrequency ablation for HCC: More questions than answers. <i>Journal of Hepatology</i> , 2020, 73, 972-973.	3.7	0
45	Is computed tomographyâ€enhanced clinical significant portal hypertension surrogate an authentic prognostic predictor for surgical hepatocellular carcinoma?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 2289-2289.	2.8	0
46	A comparison of prognoses between surgical resection and radiofrequency ablation therapy for patients with hepatocellular carcinoma and esophagogastric varices. <i>Scientific Reports</i> , 2020, 10, 17259.	3.3	7
47	Tumour burden score for hepatocellular carcinoma: Is it an authentic prognostic marker?. <i>British Journal of Surgery</i> , 2020, 107, e625-e625.	0.3	0
48	Judicious use of sodium-glucose cotransporter 2 inhibitors in patients with diabetes on coronavirus-19 pandemic. <i>Journal of the Chinese Medical Association</i> , 2020, 83, 809-811.	1.4	2
49	Microvascular Invasion as a Prognostic Predictor in Hepatocellular Carcinoma: How Accurate Is It?. <i>Liver Cancer</i> , 2020, 9, 787-788.	7.7	3
50	Metavir Fibrosis Stage in Hepatitis Câ€Related Hepatocellular Carcinoma and Association with Noninvasive Liver Reserve Models. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 1860-1862.	1.7	1
51	Survival of Patients with Hepatocellular Carcinoma in Renal Insufficiency: Prognostic Role of Albumin-Bilirubin Grade. <i>Cancers</i> , 2020, 12, 1130.	3.7	10
52	Treating Small Hepatocellular Carcinoma: Stereotactic Body Radiation Therapy Versus Radiofrequency Ablation. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 2020-2020.	2.8	1
53	Gastrointestinal and liver manifestations in patients with COVID-19. <i>Journal of the Chinese Medical Association</i> , 2020, 83, 521-523.	1.4	165
54	Thrombocytosis is associated with worse survival in patients with hepatocellular carcinoma. <i>Liver International</i> , 2020, 40, 2522-2534.	3.9	20

#	ARTICLE	IF	CITATIONS
55	Nomogram to predict surgical hepatocellular carcinoma with Child-Pugh B: Feasibility and overlooked predictors. <i>Journal of Hepatology</i> , 2020, 72, 1032-1033.	3.7	2
56	Evolution of etiology, presentation, management and prognostic tool in hepatocellular carcinoma. <i>Scientific Reports</i> , 2020, 10, 3925.	3.3	18
57	Liver stiffness measured by acoustic radiation force impulse elastography predicted prognoses of hepatocellular carcinoma after radiofrequency ablation. <i>Scientific Reports</i> , 2020, 10, 2006.	3.3	7
58	Differential Survival Impact of Diabetes Mellitus on Hepatocellular Carcinoma: Role of Staging Determinants. <i>Digestive Diseases and Sciences</i> , 2020, 65, 3389-3402.	2.3	2
59	Comparison of prognosis between surgical resection and transarterial chemoembolization for patients with solitary huge hepatocellular carcinoma. <i>Annals of Translational Medicine</i> , 2020, 8, 238-238.	1.7	17
60	Development of polydimethylsiloxane-based biomimetic scaffolds with cylinder micropillars for retinal pigment epithelial cell cultivation. <i>Journal of the Chinese Medical Association</i> , 2020, 83, 1029-1033.	1.4	1
61	ALBI grade as a new player in hepatocellular carcinoma. <i>Journal of the Chinese Medical Association</i> , 2019, 82, 1.	1.4	20
62	A new ALBI-based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinoma. <i>Liver International</i> , 2019, 39, 1704-1712.	3.9	58
63	SAT-462-Current non-invasive liver reserve models do not predict histological fibrosis severity in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2019, 70, e836-e837.	3.7	0
64	Ash2l interacts with Oct4-stemness circuitry to promote super-enhancer-driven pluripotency network. <i>Nucleic Acids Research</i> , 2019, 47, 10115-10133.	14.5	20
65	SAT-463-Albumin-bilirubin grade-based nomogram to predict tumor recurrence in patients with hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2019, 70, e837-e838.	3.7	0
66	Predicting post-resection recurrence of hepatocellular carcinoma: Spleen stiffness vs. ALBI grade. <i>Journal of Hepatology</i> , 2019, 70, 808.	3.7	1
67	Dual Delivery of HNF4 α and Cisplatin by Mesoporous Silica Nanoparticles Inhibits Cancer Pluripotency and Tumorigenicity in Hepatoma-Derived CD133-Expressing Stem Cells. <i>ACS Applied Materials & Interfaces</i> , 2019, 11, 19808-19818.	8.0	40
68	Folic acid ameliorates homocysteine-induced angiogenesis and portosystemic collaterals in cirrhotic rats. <i>Annals of Hepatology</i> , 2019, 18, 633-639.	1.5	2
69	An Albumin-Bilirubin (ALBI) Grade-based Prognostic Model For Patients With Hepatocellular Carcinoma Within Milan Criteria. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 698-704.	1.3	15
70	Proton Pump Inhibitors and Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B or C. <i>Hepatology</i> , 2019, 69, 1151-1164.	7.3	22
71	Albumin-bilirubin (ALBI) grade-based nomogram to predict tumor recurrence in patients with hepatocellular carcinoma. <i>European Journal of Surgical Oncology</i> , 2019, 45, 776-781.	1.0	38
72	Staging and Restaging for Hepatocellular Carcinoma: Solution of Confusion?. <i>Hepatology</i> , 2019, 69, 464-465.	7.3	0

#	ARTICLE	IF	CITATIONS
73	Magic mirror on the wall: Which is the best biomarker for hepatocellular carcinoma?. <i>Hepatology</i> , 2018, 67, 2482-2483.	7.3	3
74	Metastasis in patients with hepatocellular carcinoma: Prevalence, determinants, prognostic impact and ability to improve the Barcelona Clinic Liver Cancer system. <i>Liver International</i> , 2018, 38, 1803-1811.	3.9	18
75	Prognostic Performance of Ten Liver Function Models in Patients with Hepatocellular Carcinoma Undergoing Radiofrequency Ablation. <i>Scientific Reports</i> , 2018, 8, 843.	3.3	25
76	Detecting microvascular invasion in HCC with contrast-enhanced MRI: Is it a good idea?. <i>Journal of Hepatology</i> , 2018, 68, 862-863.	3.7	2
77	Using nomogram of the Barcelona Clinic Liver Cancer system for treatment selection in patients with stage C hepatocellular carcinoma. <i>BMC Cancer</i> , 2018, 18, 289.	2.6	19
78	Comparison of twelve liver functional reserve models for outcome prediction in patients with hepatocellular carcinoma undergoing surgical resection. <i>Scientific Reports</i> , 2018, 8, 4773.	3.3	26
79	Validation of the albuminâ€bilirubin gradeâ€based integrated model as a predictor for sorafenibâ€failed hepatocellular carcinoma. <i>Liver International</i> , 2018, 38, 321-330.	3.9	37
80	Esophageal varices are not predictive of patient prognosis after surgical resection of hepatocellular carcinoma. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 1368-1377.	1.6	7
81	Correlation and prognostic accuracy between noninvasive liver fibrosis markers and portal pressure in cirrhosis: Role of ALBI score. <i>PLoS ONE</i> , 2018, 13, e0208903.	2.5	30
82	Current noninvasive liver reserve models do not predict histological fibrosis severity in hepatocellular carcinoma. <i>Scientific Reports</i> , 2018, 8, 15074.	3.3	8
83	Insulin reverses major portal hypertension-related derangements in rats with liver cirrhosis and diabetes. <i>Clinical Science</i> , 2018, 132, 2391-2405.	4.3	4
84	Development of a Graphene Oxide-Incorporated Polydimethylsiloxane Membrane with Hexagonal Micropillars. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2517.	4.1	6
85	The effects of proton pump inhibitor on hepatic vascular responsiveness and hemodynamics in cirrhotic rats. <i>Journal of the Chinese Medical Association</i> , 2018, 81, 585-592.	1.4	0
86	Comparison of twelve noninvasive liver reserve models in HCC patients undergoing resection. <i>Journal of Hepatology</i> , 2018, 68, S640.	3.7	0
87	The effect of primary prophylaxis therapy for large esophageal varices in patients with hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2018, 68, S713.	3.7	0
88	Hepatocellular Carcinoma with Portal Vein Tumor Involvement: Best Management Strategies. <i>Seminars in Liver Disease</i> , 2018, 38, 242-251.	3.6	95
89	Correlation and prognostic accuracy between noninvasive liver reserve markers and portal pressure in cirrhosis: Role of ALBI score. <i>Journal of Hepatology</i> , 2018, 68, S736-S737.	3.7	0
90	The Prognosis of Single Large Hepatocellular Carcinoma Was Distinct from Barcelona Clinic Liver Cancer Stage A or B: The Role of Albumin-Bilirubin Grade. <i>Liver Cancer</i> , 2018, 7, 335-358.	7.7	27

#	ARTICLE	IF	CITATIONS
91	Ablation for Hepatocellular Carcinoma. <i>Annals of Surgery</i> , 2017, 266, e55-e56.	4.2	0
92	Treating Very Early-stage HCC. <i>Annals of Surgery</i> , 2017, 266, e31-e32.	4.2	2
93	The impact of esophagogastric varices on the prognosis of patients with hepatocellular carcinoma. <i>Scientific Reports</i> , 2017, 7, 42577.	3.3	25
94	Hepatocellular Carcinoma: Nomograms Based on the Albumin-Bilirubin Grade to Assess the Outcomes of Radiofrequency Ablation. <i>Radiology</i> , 2017, 285, 670-680.	7.3	88
95	A New Treatment-integrated Prognostic Nomogram of the Barcelona Clinic Liver Cancer System for Hepatocellular Carcinoma. <i>Scientific Reports</i> , 2017, 7, 7914.	3.3	6
96	Comment on "Transarterial chemo-embolisation of hepatocellular carcinoma: impact of liver function and vascular invasion". <i>British Journal of Cancer</i> , 2017, 117, e5-e5.	6.4	2
97	Performance status in patients with HCC: New kid on the block. <i>Journal of Hepatology</i> , 2017, 67, 1352-1353.	3.7	3
98	Pharmacokinetics of Rhodamine 110 and Its Organ Distribution in Rats. <i>Journal of Agricultural and Food Chemistry</i> , 2017, 65, 7797-7804.	5.2	3
99	ALBI Score as a Novel Tool in Staging and Treatment Planning for Hepatocellular Carcinoma: Is It Sufficient. <i>Liver Cancer</i> , 2017, 6, 375-376.	7.7	2
100	Ascorbate lacks significant influence in rats with bile duct ligation-induced liver injury. <i>Journal of the Chinese Medical Association</i> , 2017, 80, 539-550.	1.4	3
101	Higher platelet counts are associated with metabolic syndrome independent of fatty liver diagnosis. <i>Journal of the Chinese Medical Association</i> , 2017, 80, 125-132.	1.4	24
102	The impact of clinically significant portal hypertension on the prognosis of patients with hepatocellular carcinoma after radiofrequency ablation: a propensity score matching analysis. <i>European Radiology</i> , 2017, 27, 2600-2609.	4.5	13
103	ALBI and PALBI grade predict survival for HCC across treatment modalities and BCLC stages in the MELD Era. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 879-886.	2.8	126
104	Prognostic impact of diabetes mellitus on hepatocellular carcinoma: Special emphasis from the BCLC perspective. <i>PLoS ONE</i> , 2017, 12, e0174333.	2.5	14
105	Risk of recurrence in chronic hepatitis B patients developing hepatocellular carcinoma with antiviral secondary prevention failure. <i>PLoS ONE</i> , 2017, 12, e0188552.	2.5	6
106	Fatty Liver Index and Lipid Accumulation Product Can Predict Metabolic Syndrome in Subjects without Fatty Liver Disease. <i>Gastroenterology Research and Practice</i> , 2017, 2017, 1-12.	1.5	14
107	Prognostic role of noninvasive liver reserve markers in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. <i>PLoS ONE</i> , 2017, 12, e0180408.	2.5	31
108	Impact of tumor burden on prognostic prediction for patients with terminal stage hepatocellular carcinoma: A nomogram study. <i>PLoS ONE</i> , 2017, 12, e0188031.	2.5	14

#	ARTICLE	IF	CITATIONS
109	2'-OH-Flavone ameliorates mesenteric angiogenesis and portal-systemic collaterals in rats with liver fibrosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1045-1051.	2.8	6
110	Surgical Resection Versus Radiofrequency Ablation for Single Hepatocellular Carcinoma ≤ 2 cm in a Propensity Score Model. <i>Annals of Surgery</i> , 2016, 263, 538-545.	4.2	148
111	Utility of prognostic scoring systems in management of hepatocellular carcinoma. <i>European Journal of Cancer</i> , 2016, 68, 206-207.	2.8	1
112	Antiplatelet Therapy is Associated with a Better Prognosis for Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma after Liver Resection. <i>Annals of Surgical Oncology</i> , 2016, 23, 874-883.	1.5	51
113	Predictors of response to pegylated interferon in chronic hepatitis B: a real-world hospital-based analysis. <i>Scientific Reports</i> , 2016, 6, 29605.	3.3	37
114	Nomogram of the Barcelona clinic liver cancer system: on the go. <i>Liver International</i> , 2016, 36, 1717-1718.	3.9	2
115	Proposal and validation of a new model to estimate survival for hepatocellular carcinoma patients. <i>European Journal of Cancer</i> , 2016, 63, 25-33.	2.8	40
116	Nomogram of the Barcelona Clinic Liver Cancer system for individual prognostic prediction in hepatocellular carcinoma. <i>Liver International</i> , 2016, 36, 1498-1506.	3.9	25
117	Reply to "Hepatocellular carcinoma scoring and staging systems. Do we need new tools?". <i>Journal of Hepatology</i> , 2016, 64, 1450-1452.	3.7	3
118	Prognosis of hepatocellular carcinoma: Assessment of eleven staging systems. <i>Journal of Hepatology</i> , 2016, 64, 601-608.	3.7	220
119	Surgical Resection is Better than Transarterial Chemoembolization for Patients with Hepatocellular Carcinoma Beyond the Milan Criteria: A Prognostic Nomogram Study. <i>Annals of Surgical Oncology</i> , 2016, 23, 994-1002.	1.5	38
120	Clopidogrel inhibits angiogenesis of gastric ulcer healing via downregulation of vascular endothelial growth factor receptor 2. <i>Journal of the Formosan Medical Association</i> , 2016, 115, 764-772.	1.7	30
121	Solitary Large Hepatocellular Carcinoma: Staging and Treatment Strategy. <i>PLoS ONE</i> , 2016, 11, e0155588.	2.5	37
122	Hepatocellular Carcinoma Patients With Performance Status 1 Deserve New Classification and Treatment Algorithm in the BCLC System. <i>Medicine (United States)</i> , 2015, 94, e1223.	1.0	11
123	When to Perform Surgical Resection or Radiofrequency Ablation for Early Hepatocellular Carcinoma?. <i>Medicine (United States)</i> , 2015, 94, e1808.	1.0	26
124	Enhanced Antioxidant Capacity of Dental Pulp-Derived iPSC-Differentiated Hepatocytes and Liver Regeneration by Injectable HGF-Releasing Hydrogel in Fulminant Hepatic Failure. <i>Cell Transplantation</i> , 2015, 24, 541-559.	2.5	30
125	Interleukin-1 receptor antagonist correlates with hepatic venous pressure gradient and predicts occurrence of overall complications and bacterial infections in patients with cirrhosis. <i>Hepatology Research</i> , 2015, 45, 294-304.	3.4	3
126	Impact of renal insufficiency on patients with hepatocellular carcinoma undergoing radiofrequency ablation. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 192-198.	2.8	4

#	ARTICLE	IF	CITATIONS
127	Surgery for advanced hepatocellular carcinoma: Time to take action. <i>Journal of Surgical Oncology</i> , 2015, 112, 909-909.	1.7	0
128	Active Treatments Prolong the Survival in Patients With Hepatocellular Carcinoma and Performance Status 3 or 4. <i>Journal of Clinical Gastroenterology</i> , 2015, 49, 878-884.	2.2	3
129	External Validation of Fatty Liver Index for Identifying Ultrasonographic Fatty Liver in a Large-Scale Cross-Sectional Study in Taiwan. <i>PLoS ONE</i> , 2015, 10, e0120443.	2.5	105
130	The Beneficial Effects of P2X7 Antagonism in Rats with Bile Duct Ligation-induced Cirrhosis. <i>PLoS ONE</i> , 2015, 10, e0124654.	2.5	26
131	Prognosis of Early-Stage Hepatocellular Carcinoma. <i>Medicine (United States)</i> , 2015, 94, e1929.	1.0	32
132	Determinants of Survival After Sorafenib Failure in Patients With BCLC-C Hepatocellular Carcinoma in Real-World Practice. <i>Medicine (United States)</i> , 2015, 94, e688.	1.0	30
133	Hong Kong Liver Cancer Staging System Is Associated With Better Performance for Hepatocellular Carcinoma. <i>Medicine (United States)</i> , 2015, 94, e1772.	1.0	21
134	Diabetes enhances the intrahepatic vascular response to endothelin-1 in cirrhotic rats: association with the ET _A receptor and pERK α regulation. <i>Liver International</i> , 2015, 35, 704-712.	3.9	2
135	Synergistic effects of carboxymethyl-hexanoyl chitosan, cationic polyurethane-short branch PEI in miR122 gene delivery: Accelerated differentiation of iPSCs into mature hepatocyte-like cells and improved stem cell therapy in a hepatic failure model. <i>Acta Biomaterialia</i> , 2015, 13, 228-244.	8.3	41
136	Aggressive Therapeutic Strategies Improve the Survival of Hepatocellular Carcinoma Patients with Performance Status 1 or 2: A Propensity Score Analysis. <i>Annals of Surgical Oncology</i> , 2015, 22, 1324-1331.	1.5	18
137	Surgical resection versus transarterial chemoembolization for BCLC stage C hepatocellular carcinoma. <i>Journal of Surgical Oncology</i> , 2015, 111, 404-409.	1.7	25
138	Radiofrequency Ablation is Better Than Surgical Resection in Patients With Hepatocellular Carcinoma Within the Milan Criteria and Preserved Liver Function. <i>Journal of Clinical Gastroenterology</i> , 2015, 49, 242-249.	2.2	33
139	The Impact of Spironolactone on the Severity of Portal-Systemic Collaterals and Hepatic Encephalopathy in Cirrhotic Rats. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2015, 355, 117-124.	2.5	9
140	Using Serum α -Fetoprotein for Prognostic Prediction in Patients with Hepatocellular Carcinoma: What is the Most Optimal Cutoff?. <i>PLoS ONE</i> , 2015, 10, e0118825.	2.5	36
141	Anti-hepatitis C virus seropositivity is not associated with metabolic syndrome irrespective of age, gender and fibrosis. <i>Annals of Hepatology</i> , 2015, 14, 181-9.	1.5	12
142	A New Child-Turcotte-Pugh Class 0 for Patients with Hepatocellular Carcinoma: Determinants, Prognostic Impact and Ability to Improve the Current Staging Systems. <i>PLoS ONE</i> , 2014, 9, e99115.	2.5	8
143	Uncompromised Treatment Efficacy in Elderly Patients With Hepatocellular Carcinoma. <i>Medicine (United States)</i> , 2014, 93, e264.	1.0	20
144	Vascular Invasion in Hepatocellular Carcinoma. <i>Journal of Clinical Gastroenterology</i> , 2014, 48, 734-741.	2.2	68

#	ARTICLE	IF	CITATIONS
145	Surgical Resection Versus Transarterial Chemoembolization for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Propensity Score Analysis. <i>Annals of Surgical Oncology</i> , 2014, 21, 1825-1833.	1.5	93
146	Pharmacokinetics of Ractopamine and Its Organ Distribution in Rats. <i>Journal of Agricultural and Food Chemistry</i> , 2014, 62, 9273-9278.	5.2	18
147	Survival Advantage of Radiofrequency Ablation Over Transarterial Chemoembolization for Patients with Hepatocellular Carcinoma and Good Performance Status Within the Milan Criteria. <i>Annals of Surgical Oncology</i> , 2014, 21, 3835-3843.	1.5	19
148	Surgical Resection Is Better than Transarterial Chemoembolization for Hepatocellular Carcinoma Beyond Milan Criteria Independent of Performance Status. <i>Journal of Gastrointestinal Surgery</i> , 2014, 18, 1623-1631.	1.7	18
149	A Comparison of Clinical Manifestations and Prognoses Between Patients with Hepatocellular Carcinoma and Child-Pugh Scores of 5 or 6. <i>Medicine (United States)</i> , 2014, 93, e348.	1.0	17
150	Decrypting Cryptogenic Hepatocellular Carcinoma: Clinical Manifestations, Prognostic Factors and Long-Term Survival by Propensity Score Model. <i>PLoS ONE</i> , 2014, 9, e89373.	2.5	13
151	Gallic Acid Ameliorated Impaired Glucose and Lipid Homeostasis in High Fat Diet-Induced NAFLD Mice. <i>PLoS ONE</i> , 2014, 9, e96969.	2.5	143
152	Induced pluripotent stem cells and hepatic differentiation. <i>Journal of the Chinese Medical Association</i> , 2013, 76, 599-605.	1.4	13
153	Î±-Fetoprotein-to-Total Tumor Volume Ratio Predicts Post-operative Tumor Recurrence in Hepatocellular Carcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2013, 17, 730-738.	1.7	23
154	Alcoholism worsens the survival of patients with hepatitis B virus and C virus-related hepatocellular carcinoma. <i>Hepatology International</i> , 2013, 7, 645-654.	4.2	17
155	Ascites in patients with hepatocellular carcinoma: prevalence, associated factors, prognostic impact, and staging strategy. <i>Hepatology International</i> , 2013, 7, 188-198.	4.2	36
156	Total Tumor Volume Is a Better Marker of Tumor Burden in Hepatocellular Carcinoma Defined by the Milan Criteria. <i>World Journal of Surgery</i> , 2013, 37, 1348-1355.	1.6	26
157	Validation of the behavior and concept based assessment of professionalism competence in postgraduate first-year residents. <i>Journal of the Chinese Medical Association</i> , 2013, 76, 186-194.	1.4	6
158	Performance Status Enhances the Selection of Treatment for Patients with Hepatocellular Carcinoma Within the Milan Criteria. <i>Annals of Surgical Oncology</i> , 2013, 20, 2035-2042.	1.5	17
159	Performance status in patients with hepatocellular carcinoma: Determinants, prognostic impact, and ability to improve the Barcelona Clinic Liver Cancer system. <i>Hepatology</i> , 2013, 57, 112-119.	7.3	168
160	Assessing liver dysfunction in cirrhosis: Role of the model for end-stage liver disease and its derived systems. <i>Journal of the Chinese Medical Association</i> , 2013, 76, 419-424.	1.4	6
161	Hepatocellular carcinoma in uremic patients: Is there evidence for an increased risk of mortality?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 348-356.	2.8	11
162	Serum interferon gamma level predicts recurrence in hepatocellular carcinoma patients after curative treatments. <i>International Journal of Cancer</i> , 2013, 133, 2895-2902.	5.1	49

#	ARTICLE	IF	CITATIONS
163	Inverse Association between Hepatitis B Virus Infection and Fatty Liver Disease: A Large-Scale Study in Populations Seeking for Check-Up. PLoS ONE, 2013, 8, e72049.	2.5	76
164	CXCL9 Associated with Sustained Virological Response in Chronic Hepatitis B Patients Receiving Peginterferon Alfa-2a Therapy: A Pilot Study. PLoS ONE, 2013, 8, e76798.	2.5	18
165	Comparison of prognosis by viral etiology in patients with hepatocellular carcinoma after radiofrequency ablation. Annals of Hepatology, 2013, 12, 263-273.	1.5	18
166	IL28B Polymorphism Correlates with Active Hepatitis in Patients with HBeAg-Negative Chronic Hepatitis B. PLoS ONE, 2013, 8, e58071.	2.5	26
167	The Influence of Hepatitis B Viral Load and Pre-S Deletion Mutations on Post-Operative Recurrence of Hepatocellular Carcinoma and the Tertiary Preventive Effects by Anti-Viral Therapy. PLoS ONE, 2013, 8, e66457.	2.5	67
168	Diabetes Diminishes the Portal-Systemic Collateral Vascular Response to Vasopressin via Vasopressin Receptor and Gl \pm Proteins Regulations in Cirrhotic Rats. PLoS ONE, 2013, 8, e67703.	2.5	4
169	Improvement of Carbon Tetrachloride-Induced Acute Hepatic Failure by Transplantation of Induced Pluripotent Stem Cells without Reprogramming Factor c-Myc. International Journal of Molecular Sciences, 2012, 13, 3598-3617.	4.1	18
170	Prognostic Significance of Computed Tomography Scan-derived Splenic Volume in Hepatocellular Carcinoma Treated With Radiofrequency Ablation. Journal of Clinical Gastroenterology, 2012, 46, 789-795.	2.2	19
171	Younger Hepatocellular Carcinoma Patients Have Better Prognosis After Percutaneous Radiofrequency Ablation Therapy. Journal of Clinical Gastroenterology, 2012, 46, 62-70.	2.2	56
172	Commentary: predicting survival in hepatocellular carcinoma patients – authors’ reply. Alimentary Pharmacology and Therapeutics, 2012, 36, 681-681.	3.7	0
173	Selecting a prognostic renal surrogate for patients with hepatocellular carcinoma undergoing transarterial chemoembolization. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 1581-1588.	2.8	11
174	Vandetanib in patients with inoperable hepatocellular carcinoma: A phase II, randomized, double-blind, placebo-controlled study. Journal of Hepatology, 2012, 56, 1097-1103.	3.7	91
175	Serum alpha-fetoprotein response can predict prognosis in hepatocellular carcinoma patients undergoing radiofrequency ablation therapy. Clinical Radiology, 2012, 67, 429-436.	1.1	42
176	Comparison of Surgical Resection and Transarterial Chemoembolization for Hepatocellular Carcinoma beyond the Milan Criteria: A Propensity Score Analysis. Annals of Surgical Oncology, 2012, 19, 842-849.	1.5	108
177	Defining the severity of liver dysfunction in patients with hepatocellular carcinoma by the model for end-stage liver disease-derived systems. Digestive and Liver Disease, 2012, 44, 868-874.	0.9	10
178	Outcome After Percutaneous Cholecystostomy for Acute Cholecystitis: a Single-Center Experience. Journal of Gastrointestinal Surgery, 2012, 16, 1860-1868.	1.7	66
179	Transarterial chemoembolization can prolong survival for patients with metastatic hepatocellular carcinoma: a propensity score matching analysis. Hepatology International, 2012, 6, 753-762.	4.2	20
180	A prognostic model for patients with hepatocellular carcinoma within the Milan criteria undergoing non-transplant therapies, based on 1106 patients. Alimentary Pharmacology and Therapeutics, 2012, 36, 551-559.	3.7	11

#	ARTICLE	IF	CITATIONS
181	Differential prognostic impact of renal insufficiency on patients with hepatocellular carcinoma: A propensity score analysis and staging strategy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 690-699.	2.8	12
182	The Role of Interferon- β Inducible Protein-10 in a Mouse Model of Acute Liver Injury Post Induced Pluripotent Stem Cells Transplantation. <i>PLoS ONE</i> , 2012, 7, e50577.	2.5	11
183	Hepatitis B and Hepatocellular Carcinoma and Their Treatment. , 2012, , 119-141.		0
184	Survival Rates Are Comparable After Radiofrequency Ablation or Surgery in Patients With Small Hepatocellular Carcinomas. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 79-86.	4.4	151
185	Risk factors for long-term prognosis in hepatocellular carcinoma after radiofrequency ablation therapy. <i>European Journal of Gastroenterology and Hepatology</i> , 2011, 23, 1.	1.6	53
186	Comparative Analysis of Noninvasive Models to Predict Early Liver Fibrosis in Hepatitis B e Antigen-negative Chronic Hepatitis B. <i>Journal of Clinical Gastroenterology</i> , 2011, 45, 278-285.	2.2	28
187	Liver Failure After Transarterial Chemoembolization for Patients With Hepatocellular Carcinoma and Ascites. <i>Journal of Clinical Gastroenterology</i> , 2011, 45, 556-562.	2.2	49
188	Impact of body mass index and viral load on liver histology in hepatitis B e antigen-negative chronic hepatitis B. <i>Clinical Nutrition</i> , 2011, 30, 647-652.	5.0	21
189	Early identification of poor responders to transarterial chemoembolization for hepatocellular carcinoma. <i>Hepatology International</i> , 2011, 5, 975-984.	4.2	13
190	Comparison of radiofrequency ablation and transarterial chemoembolization for hepatocellular carcinoma within the Milan criteria: A propensity score analysis. <i>Liver Transplantation</i> , 2011, 17, 556-566.	2.4	63
191	Reprogramming induced pluripotent stem cells in the absence of c-Myc for differentiation into hepatocyte-like cells. <i>Biomaterials</i> , 2011, 32, 5994-6005.	11.4	65
192	Transarterial chemoembolization and renal failure in hepatocellular carcinoma patients: authors' reply. <i>Liver International</i> , 2010, 30, 924-925.	3.9	0
193	Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma and Renal Insufficiency. <i>Journal of Clinical Gastroenterology</i> , 2010, 44, e171-e177.	2.2	29
194	Fibrosis and AST to platelet ratio index predict post-operative prognosis for solitary small hepatitis B-related hepatocellular carcinoma. <i>Hepatology International</i> , 2010, 4, 691-699.	4.2	60
195	Selecting an optimal staging system for hepatocellular carcinoma. <i>Cancer</i> , 2010, 116, 3006-3014.	4.1	88
196	Renal failure in patients with hepatocellular carcinoma and ascites undergoing transarterial chemoembolization. <i>Liver International</i> , 2010, 30, 77-84.	3.9	34
197	Diabetes mellitus as an independent prognostic predictor and its association with renal dysfunction in patients with hepatocellular carcinoma. <i>Liver International</i> , 2010, 30, 198-207.	3.9	30
198	Correlation between clinical indication for treatment and liver histology in HBeAg-negative chronic hepatitis B: a novel role of α -fetoprotein. <i>Liver International</i> , 2010, 30, 1161-1168.	3.9	10

#	ARTICLE	IF	CITATIONS
199	Lack of therapeutic effects of gabexate mesilate on the hepatic encephalopathy in rats with acute and chronic hepatic failure. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 1321-1328.	2.8	2
200	Selecting an optimal cutoff value for creatinine in the model for end-stage liver disease equation. <i>Clinical Transplantation</i> , 2010, 24, 157-163.	1.6	7
201	Core Antigen Expression Is Associated with Hepatic Necroinflammation in e Antigen-Negative Chronic Hepatitis B Patients with Low DNA Loads. <i>Vaccine Journal</i> , 2010, 17, 1048-1053.	3.1	7
202	Comparison of the model for end-stage liver disease (MELD), MELD-Na and MELDNa for outcome prediction in patients with acute decompensated hepatitis. <i>Digestive and Liver Disease</i> , 2010, 42, 137-142.	0.9	35
203	A new prognostic model for hepatocellular carcinoma based on total tumor volume: The Taipei Integrated Scoring system. <i>Journal of Hepatology</i> , 2010, 53, 108-117.	3.7	157
204	The Global Spread of 2009 H1N1 Influenza: A False Pandemic?. <i>Journal of the Chinese Medical Association</i> , 2010, 73, 60-61.	1.4	2
205	The First Case of Multidrug-resistant NDM-1-harboring Enterobacteriaceae in Taiwan: Here Comes the Superbacteria!. <i>Journal of the Chinese Medical Association</i> , 2010, 73, 557-558.	1.4	22
206	Major adverse events, pretransplant assessment and outcome prediction. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 1716-1724.	2.8	7
207	Characteristics and outcome of patients with dual hepatitis B and C-associated hepatocellular carcinoma: are they different from patients with single virus infection?. <i>Liver International</i> , 2009, 29, 767-773.	3.9	19
208	Generation of cytotoxicity against hepatitis delta virus genotypes and quasispecies by epitope modification. <i>Journal of Hepatology</i> , 2009, 50, 779-788.	3.7	4
209	Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2009, 51, 890-897.	3.7	369
210	Selecting a Short-term Prognostic Model for Hepatocellular Carcinoma. <i>Journal of Clinical Gastroenterology</i> , 2009, 43, 773-781.	2.2	21
211	Predictive Value of Aspartate Aminotransferase to Alanine Aminotransferase Ratio for Hepatic Fibrosis and Clinical Adverse Outcomes in Patients With Primary Biliary Cirrhosis. <i>Journal of Clinical Gastroenterology</i> , 2009, 43, 876-883.	2.2	25
212	Comparison of four model for end-stage liver disease-based prognostic systems for cirrhosis. <i>Liver Transplantation</i> , 2008, 14, 837-844.	2.4	50
213	Natural history and prognostic factors of primary biliary cirrhosis in Taiwan: a follow-up study up to 18 years. <i>Liver International</i> , 2008, 28, 1305-1313.	3.9	23
214	Selecting an optimal prognostic system for liver cirrhosis: the model for end-stage liver disease and beyond. <i>Liver International</i> , 2008, 28, 606-613.	3.9	77
215	Metastatic hepatocellular carcinoma: when, how, where and so what?. <i>Liver International</i> , 2008, 28, 1183-1185.	3.9	6
216	Validation of the HCC-MELD for dropout probability in patients with small hepatocellular carcinoma undergoing locoregional therapy. <i>Clinical Transplantation</i> , 2008, 22, 469-475.	1.6	34

#	ARTICLE	IF	CITATIONS
217	The MELD-Na is an independent short- and long-term prognostic predictor for hepatocellular carcinoma: A prospective survey. <i>Digestive and Liver Disease</i> , 2008, 40, 882-889.	0.9	48
218	Successful Radiofrequency Ablation Therapy for Hepatocellular Carcinoma in a Male Patient with Early Stage Primary Biliary Cirrhosis and Positive Serum Hepatitis B Core Antibody. <i>Journal of the Chinese Medical Association</i> , 2008, 71, 40-44.	1.4	1
219	Cholestatic Jaundice as the Predominant Presentation in a Patient with Autoimmune Hepatitis. <i>Journal of the Chinese Medical Association</i> , 2008, 71, 45-48.	1.4	4
220	The Model for End-Stage Liver Disease Based Cancer Staging Systems Are Better Prognostic Models for Hepatocellular Carcinoma: A Prospective Sequential Survey. <i>American Journal of Gastroenterology</i> , 2007, 102, 1920-1930.	0.4	65
221	Survival impact of delayed treatment in patients with hepatocellular carcinoma undergoing locoregional therapy: Is there a lead-time bias?. <i>Scandinavian Journal of Gastroenterology</i> , 2007, 42, 485-492.	1.5	27
222	Is the Corrected-Creatinine Model for End-Stage Liver Disease a Feasible Strategy to Adjust Gender Difference in Organ Allocation for Liver Transplantation?. <i>Transplantation</i> , 2007, 84, 1406-1412.	1.0	44
223	Correlation and Comparison of the Model for End-stage Liver Disease, Portal Pressure, and Serum Sodium for Outcome Prediction in Patients With Liver Cirrhosis. <i>Journal of Clinical Gastroenterology</i> , 2007, 41, 706-712.	2.2	36
224	Does hepatitis B viral load determine the outcome of patients with hepatocellular carcinoma undergoing chemotherapy?. <i>Hepatology</i> , 2007, 46, 1665-1666.	7.3	0
225	To MELD or not to MELD, that is a question. <i>Liver Transplantation</i> , 2007, 13, 1618-1618.	2.4	2
226	The predictive ability of serum α -fetoprotein for hepatocellular carcinoma is linked with the characteristics of the target population at surveillance. <i>Journal of Surgical Oncology</i> , 2007, 95, 645-651.	1.7	11
227	Model for end-stage liver disease score to serum sodium ratio index as a prognostic predictor and its correlation with portal pressure in patients with liver cirrhosis. <i>Liver International</i> , 2007, 27, 498-506.	3.9	96
228	Model for End-stage Liver Disease and Organ Allocation in Liver Transplantation: Where Are We and Where Should We Go?. <i>Journal of the Chinese Medical Association</i> , 2006, 69, 193-198.	1.4	13
229	The Sequential Changes of the Model for End-stage Liver Disease Score Correlate With the Severity of Liver Cirrhosis in Patients With Hepatocellular Carcinoma Undergoing Locoregional Therapy. <i>Journal of Clinical Gastroenterology</i> , 2006, 40, 543-550.	2.2	17
230	Fever and Infectious Complications After Percutaneous Acetic Acid Injection Therapy for Hepatocellular Carcinoma: Incidence and Risk Factor Analysis. <i>Journal of Clinical Gastroenterology</i> , 2006, 40, 639-642.	2.2	7
231	Limitation of the model for end-stage liver disease for outcome prediction in patients with cirrhosis-related complications. <i>Clinical Transplantation</i> , 2006, 20, 188-194.	1.6	60
232	Occurrence of cirrhosis-related complications is a time-dependent prognostic predictor independent of baseline model for end-stage liver disease score. <i>Liver International</i> , 2006, 26, 55-61.	3.9	35
233	Role of the model for end-stage liver disease and serum α -fetoprotein as prognostic predictors for hepatocellular carcinoma. <i>Liver International</i> , 2006, 26, 1300-1301.	3.9	3
234	Association of core promoter/precore mutations and viral load in e antigen-negative chronic hepatitis B patients. <i>Journal of Viral Hepatitis</i> , 2006, 13, 336-342.	2.0	25

#	ARTICLE	IF	CITATIONS
235	Survival benefit of transcatheter arterial chemoembolization in patients with hepatocellular carcinoma larger than 10 cm in diameter. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 23, 129-135.	3.7	61
236	The model for end-stage liver disease-based Japan Integrated Scoring system may have a better predictive ability for patients with hepatocellular carcinoma undergoing locoregional therapy. <i>Cancer</i> , 2006, 107, 141-148.	4.1	54
237	Hepatitis after arterial embolization for hepatocellular carcinoma: Viral reactivation or ischemia?. <i>Hepatology</i> , 2006, 43, 1400-1401.	7.3	7
238	Proposal of a modified Child-Turcotte-Pugh scoring system and comparison with the model for end-stage liver disease for outcome prediction in patients with cirrhosis. <i>Liver Transplantation</i> , 2006, 12, 65-71.	2.4	74
239	Role of locoregional therapy for hepatocellular carcinoma before liver transplantation: Answer or myth?. <i>Liver Transplantation</i> , 2006, 12, 1560-1560.	2.4	1
240	Proposal of a Modified Cancer of the Liver Italian Program Staging System Based on the Model for End-Stage Liver Disease for Patients with Hepatocellular Carcinoma Undergoing Loco-Regional Therapy. <i>American Journal of Gastroenterology</i> , 2006, 101, 975-982.	0.4	47
241	Different Model for End-Stage Liver Disease Score Block Distributions May Have a Variable Ability for Outcome Prediction. <i>Transplantation</i> , 2005, 80, 1414-1418.	1.0	21
242	The role of transcatheter arterial embolization for patients with unresectable hepatocellular carcinoma: a nationwide, multicentre study evaluated by cancer stage. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 21, 687-694.	3.7	33
243	Staging for hepatocellular carcinoma: Treatment strategy matters. <i>Hepatology</i> , 2005, 41, 678-678.	7.3	8
244	Which is the holy grail in liver transplantation: Hyponatremia, MELD, or a combination?. <i>Liver Transplantation</i> , 2005, 11, 710-710.	2.4	0
245	Is there an ideal prognostic model for hepatocellular carcinoma?. <i>Gut</i> , 2005, 54, 1348-1348.	12.1	6
246	Percutaneous Ablation Therapy for Hepatocellular Carcinoma: Current Practice and Future Perspectives. <i>Journal of the Chinese Medical Association</i> , 2005, 68, 155-159.	1.4	35
247	Evaluation of the increase in model for end-stage liver disease (MELD) score over time as a prognostic predictor in patients with advanced cirrhosis: risk factor analysis and comparison with initial MELD and Child-Turcotte-Pugh score. <i>Journal of Hepatology</i> , 2005, 42, 826-832.	3.7	135
248	MELD in liver transplantation: the da Vinci code for the Holy Grail?. <i>Journal of Hepatology</i> , 2005, 42, 477-478.	3.7	11
249	Differential Mechanism and Prognostic Impact of Diabetes Mellitus on Patients with Hepatocellular Carcinoma Undergoing Surgical and Nonsurgical Treatment. <i>American Journal of Gastroenterology</i> , 2004, 99, 1479-1487.	0.4	58
250	Induction of complete tumor necrosis may reduce intrahepatic metastasis and prolong survival in patients with hepatocellular carcinoma undergoing locoregional therapy: a prospective study. <i>Annals of Oncology</i> , 2004, 15, 775-780.	1.2	22
251	Does antibody to hepatitis B surface antigen protect renal transplant patients from hepatitis B?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2004, 19, 841-843.	2.8	0
252	Management of inoperable hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2004, 19, S272-S278.	2.8	4

#	ARTICLE	IF	CITATIONS
253	Acute renal failure after transarterial chemoembolization for hepatocellular carcinoma: a retrospective study of the incidence, risk factors, clinical course and long-term outcome. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 19, 999-1007.	3.7	43
254	Comparison of transarterial chemoembolization and percutaneous acetic acid injection as the primary loco-regional therapy for unresectable hepatocellular carcinoma: a prospective survey. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 19, 1301-1308.	3.7	23
255	Incidence and risk factors for acute renal failure in patients with hepatocellular carcinoma undergoing transarterial chemoembolization: a prospective study. <i>Liver International</i> , 2004, 24, 210-215.	3.9	60
256	Deterioration of Hepatic Functional Reserve in Patients with Hepatocellular Carcinoma after Resection: Incidence, Risk Factors, and Association with Intrahepatic Tumor Recurrence. <i>World Journal of Surgery</i> , 2004, 28, 258-262.	1.6	28
257	Hepatitis C Virus Infection is a Risk Factor for Tumor Recurrence after Resection of Small Hepatocellular Carcinomas. <i>World Journal of Surgery</i> , 2004, 28, 787-791.	1.6	19
258	Contrast medium-associated renal dysfunction in patients with cirrhosis. <i>Hepatology</i> , 2004, 40, 1474-1474.	7.3	3
259	Determination of the optimal model for end-stage liver disease score in patients with small hepatocellular carcinoma undergoing loco-regional therapy. <i>Liver Transplantation</i> , 2004, 10, 1507-1513.	2.4	21
260	Changing seroepidemiology of hepatitis B, C, and D virus infections in high-risk populations. <i>Journal of Medical Virology</i> , 2004, 72, 41-45.	5.0	29
261	Reliability of contemporary radiology to measure tumour size of hepatocellular carcinoma in patients undergoing resection: limitations and clinical implications. <i>Scandinavian Journal of Gastroenterology</i> , 2004, 39, 46-52.	1.5	6
262	Persistent retention of acetic acid is associated with complete tumour necrosis in patients with hepatocellular carcinoma undergoing percutaneous acetic acid injection. <i>Scandinavian Journal of Gastroenterology</i> , 2004, 39, 168-173.	1.5	7
263	Is diabetes a risk factor for hepatocellular carcinoma?. <i>Gastroenterology</i> , 2004, 127, 360-361.	1.3	3
264	Staging for hepatocellular carcinoma: look for a perfect classification system. <i>Journal of Hepatology</i> , 2004, 40, 1041-1042.	3.7	19
265	Percutaneous injection therapy for hepatocellular carcinoma in patients with chronic renal insufficiency. <i>European Journal of Gastroenterology and Hepatology</i> , 2004, 16, 325-331.	1.6	6
266	Selective prognostic impact of serum α -fetoprotein level in patients with hepatocellular carcinoma: Analysis of 543 patients in a single center. <i>Oncology Reports</i> , 2004, 11, 543.	2.6	7
267	Selective prognostic impact of serum alpha-fetoprotein level in patients with hepatocellular carcinoma: analysis of 543 patients in a single center. <i>Oncology Reports</i> , 2004, 11, 543-50.	2.6	19
268	Analysis of clinical, biochemical and viral factors associated with early relapse after lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B patients in Taiwan. <i>Journal of Viral Hepatitis</i> , 2003, 10, 277-284.	2.0	37
269	Diabetes Mellitus Is A Risk Factor for Hepatic Decompensation in Patients With Hepatocellular Carcinoma Undergoing Resection: A Longitudinal Study. <i>American Journal of Gastroenterology</i> , 2003, 98, 2293-2298.	0.4	63
270	Sequential transarterial chemoembolization and percutaneous acetic acid injection therapy versus repeated percutaneous acetic acid injection for unresectable hepatocellular carcinoma: a prospective study. <i>Annals of Oncology</i> , 2003, 14, 1648-1653.	1.2	27

#	ARTICLE	IF	CITATIONS
271	Diabetes mellitus is a recurrence-independent risk factor in patients with hepatitis B virus-related hepatocellular carcinoma undergoing resection. <i>European Journal of Gastroenterology and Hepatology</i> , 2003, 15, 1203-1208.	1.6	30
272	Survival Benefit of Cirrhotic Patients with Hepatocellular Carcinoma Treated by Percutaneous Ethanol Injection as a Salvage Therapy. <i>Scandinavian Journal of Gastroenterology</i> , 2002, 37, 350-355.	1.5	29
273	Comparison of clinical manifestations and epidemiology between acute hepatitis A and acute hepatitis E in Taiwan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2002, 17, 1187-1191.	2.8	13
274	Ranitidine-related Stevens-Johnson syndrome in patients with severe liver diseases: A report of two cases. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2001, 16, 481-483.	2.8	12
275	Kidney transplantation in patients with chronic hepatitis B virus infection: is the prognosis worse?. <i>Digestive Diseases and Sciences</i> , 2001, 46, 469-475.	2.3	16
276	Hepatitis B virus X mutants derived from human hepatocellular carcinoma retain the ability to abrogate p53-induced apoptosis. <i>Oncogene</i> , 2001, 20, 3620-3628.	5.9	86
277	Long-term outcome of kidney transplantation in patients with hepatitis C virus infection. <i>Hepato-Gastroenterology</i> , 2001, 48, 169-73.	0.5	1
278	Prospective Case-controlled Trial of Adjuvant Chemotherapy after Resection of Hepatocellular Carcinoma. <i>World Journal of Surgery</i> , 2000, 24, 551-555.	1.6	39
279	Diabetes Mellitus as a Risk Factor of Liver Cirrhosis in Patients With Chronic Hepatitis B Virus Infection. <i>Journal of Clinical Gastroenterology</i> , 2000, 30, 250-254.	2.2	45
280	Diagnostic value of anti-hepatitis D virus (HDV) antibodies revisited: A study of total and IgM anti-HDV compared with detection of HDV-RNA by polymerase chain reaction. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1998, 13, 57-61.	2.8	19
281	Evidence of transmission of hepatitis B virus to spouses from sequence analysis of the viral genome. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1998, 13, 1138-1142.	2.8	13
282	Sero-clearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis. <i>Hepatology</i> , 1998, 28, 231-236.	7.3	233
283	Prevalence, implication, and viral nucleotide sequence analysis of GB virus-C/hepatitis G virus infection in acute fulminant and nonfulminant hepatitis. , 1998, 56, 118-122.		12
284	Decreasing hepatitis D virus infection in Taiwan: An analysis of contributory factors. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1997, 12, 747-751.	2.8	72
285	Comparison of clinico-pathological features in hepatitis B virus-associated hepatocellular carcinoma with or without hepatitis D virus superinfection. <i>Journal of Hepatology</i> , 1996, 25, 439-444.	3.7	26
286	Prognostic factor analysis of fulminant and subfulminant hepatic failure in an area endemic for hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1996, 11, 560-565.	2.8	12
287	Injection with nondisposable needles as an important route for transmission of acute community-acquired hepatitis C virus infection in Taiwan. <i>Journal of Medical Virology</i> , 1995, 46, 247-251.	5.0	48
288	Genotyping of hepatitis D virus by restriction-fragment length polymorphism and relation to outcome of hepatitis D. <i>Lancet, The</i> , 1995, 346, 939-941.	13.7	158